Lentiviral Hematopoietic Stem Cell Gene Therapy in Inherited Metabolic Disorders

dc.contributor.author	Wagemaker, Gerard
dc.date.accessioned	2020-02-13T10:53:13Z
dc.date.available	2020-02-13T10:53:13Z
dc.date.issued	2014
dc.identifier.issn	1043-0342
dc.identifier.uri	https://doi.org/10.1089/hum.2014.102
dc.identifier.uri	http://hdl.handle.net/11655/22061
dc.description.abstract	After more than 20 years of development, lentiviral hematopoietic stem cell gene therapy has entered the stage of initial clinical implementation for immune deficiencies and storage disorders. This brief review summarizes the development and applications, focusing on the lysosomal enzyme deficiencies, especially Pompe disease.	tr_TR
dc.language.iso	en	tr_TR
dc.publisher	Mary Ann Liebert, Inc	tr_TR
dc.relation.isversionof	10.1089/hum.2014.102	tr_TR
dc.rights	info:eu-repo/semantics/openAccess	tr_TR
dc.subject	Stem cell	tr_TR
dc.subject	Metabolic disorders	tr_TR
dc.subject	Lentiviral hematopoietic	tr_TR
dc.subject.lcsh	Tıp	tr_TR
dc.title	Lentiviral Hematopoietic Stem Cell Gene Therapy in Inherited Metabolic Disorders	tr_TR
dc.type	info:eu-repo/semantics/review	tr_TR
dc.type	info:eu-repo/semantics/publishedVersion
dc.relation.journal	Human Gene Therapy	tr_TR
dc.contributor.department	Kök Hücre	tr_TR
dc.identifier.volume	25	tr_TR
dc.identifier.issue	10	tr_TR
dc.identifier.startpage	862	tr_TR
dc.identifier.endpage	865	tr_TR
dc.description.index	WoS	tr_TR
dc.funding	Yok	tr_TR